Global technology investor, Amadeus Capital Partners, today announces a major expansion of its investment team. Edward Kliphuis and Kai Schmitz have joined as Partners and Ana Bernardo-Gancedo as a Healthcare Analyst.

The British Business Bank, the UK’s national economic development bank, has published its 2020 Annual Report and Accounts for this, its sixth year of operation.

Crista Galli Ventures, a new early-stage healthtech fund that offers patient capital and deep healthcare expertise, has launched this week.  Crista Galli Ventures partners with early-stage founders at Seed and Series A to build world-leading companies, and has tailored its strategy to the needs of ambitious healthtech entrepreneurs, and the unique industry in which they operate.

Finance Durham Fund has invested £750,000 in Growth Capital Ventures. The investment through Finance Durham, managed by Maven Capital Partners, will support GCV’s growth plans as it seeks to further develop its three main business units G-Labs, G-Ventures and Quva, as well as move premises to larger offices within County Durham.   

Pitchbook Data recently published their Q2 2020 Global League Tables and named SFC Capital (formerly Startup Funding Club) the Most Active Angel & Seed investor in Europe. SFC Capital is only behind SOSV and 500 Startups on the Global list of Seed investors for this period.

UK-based start-up Skin Analytics has raised £4 million in Series A funding. The funding round was led by Hoxton Ventures with participation from Nesta and Mustard Seed Ventures.

British Business Investments Ltd, a commercial subsidiary of the British Business Bank, has made its fourth commitment through its £500m Managed Funds Programme.

The cornerstone commitment of up to €75m is being made to manager Isomer Capital's second fund, Isomer Capital II. The fund will be targeted at early stage venture capital managers across Europe, that invest primarily into early stage tech companies. Isomer II will also pursue a co-investment strategy, investing alongside its fund managers, with additional capital made available for the most promising, high-growth companies from the underlying portfolio.

Bethnal Green Ventures have launched their third Tech For Good SEIS & EIS Fund for high-net-worth and sophisticated investors.

The Fund takes advantage of BGV’s wealth of experience and established brand as Europe’s leading early-stage tech for good VC. BGV aims to provide investors with a diversified portfolio of 20+ early-stage companies developing tech solutions across our three themes of a sustainable planet, a better society and healthy lives.

Following a period of sustained growth since launching Fund II in March 2019, Playfair Capital is bolstering its team in London with three new hires.

HR DataHub, the HR data benchmarking platform, has raised a £1m seed round led by the Angel CoFund and backed by an angel syndicate of seasoned HR experts including Chris Bruce and Michael Whitfield, founders of the hugely successful Thomsons Online Benefits; Oliver and Ben Black, founders of My Family Care and Tinies businesses; and HR DataHub’s new Chairman, Ian Dyke. The funding will be used to further develop and scale the platform both domestically, and internationally. 

BGF, the UK’s most active growth capital investor, has invested £3 million into 365 Response, a Wakefield-based technology business which provides mission critical transport management and eProcurement software to NHS and local government organisations, as well as private transport providers supporting the delivery of community based mobility and wellbeing services.  

Asklepios BioPharmaceutical, Inc., a leading, clinical-stage gene therapy company dedicated to developing adeno-associated virus (AAV) gene therapies for genetic disorders, has been awared a £1.99m R&D Grant from Scottish Enterprise.

AskBio will invest £3.4m alongside the grant to fund research into the manufacturing challenges associated with scaling gene therapies for widespread patient access, to further develop technologies to improve the safety and efficacy of current therapies, and to enable the treatment of genetic diseases with more complicated disease pathways that the industry is not yet able to address.